These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29384404)

  • 1. A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Zhang Y; Qu S; Wang Q; Li J; Xu Z; Qin T; Huang G; Xiao Z
    Leuk Lymphoma; 2018 Oct; 59(10):2506-2508. PubMed ID: 29384404
    [No Abstract]   [Full Text] [Related]  

  • 2. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).
    Ghazzawi M; Mehra V; Knut M; Brown L; Tapper W; Chase A; de Lavallade H; Cross NCP
    Acta Haematol; 2017; 138(4):198-200. PubMed ID: 29169164
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
    Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
    Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
    Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.
    Yoshida M; Tamagawa N; Nakao T; Kanashima H; Ueda H; Murakami A; Yorifuji T; Yamane T
    Leuk Lymphoma; 2015 Mar; 56(3):768-9. PubMed ID: 24975316
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
    Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
    Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome.
    Saultz JN; Kaffenberger BH; Taylor M; Heerema NA; Klisovic R
    JAMA Dermatol; 2016 Dec; 152(12):1391-1393. PubMed ID: 27681117
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
    Shimomura Y; Maruoka H; Ishikawa T
    Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
    Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
    Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
    [No Abstract]   [Full Text] [Related]  

  • 11. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
    Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
    Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
    Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
    Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?
    Helbig G
    Eur J Intern Med; 2016 Jul; 32():e19-20. PubMed ID: 26968968
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα.
    Tsuda K; Tanimoto T; Hayakawa K; Komatsu T
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
    Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
    Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
    [No Abstract]   [Full Text] [Related]  

  • 16. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia.
    Rosati R; La Starza R; Luciano L; Gorello P; Matteucci C; Pierini V; Romoli S; Crescenzi B; Rotoli B; Martelli MF; Pane F; Mecucci C
    Leukemia; 2006 Sep; 20(9):1623-4. PubMed ID: 16838028
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.
    Bain BJ
    Br J Haematol; 2003 Jul; 122(2):173-9. PubMed ID: 12846884
    [No Abstract]   [Full Text] [Related]  

  • 19. RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
    Such E; Liquori A; Mora E; Marco-Ayala J; Avetisyan G; Regadera A; Ibañez F; Panadero J; Senent L; Llop M; Díaz A; Vicente A; Luna I; Ibáñez M; Barragán E; Sanz MA; Sanz G; Communidad Valenciana ; Cervera J
    Acta Haematol; 2019; 142(2):92-97. PubMed ID: 31085913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Cross NC; Reiter A
    Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.